Pneumonia - info-atbvac

info-atbvac > Pneumonia

Pulmonary diffusion of dalbavancin could allow its use in the treatment of pneumonia ( Rappo U. et al. )

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.

26 mar | Dr Olivier Leroy

Pneumonia is frequently caused by gram-positive cocci including S. aureus and S. pneumoniae. Dalbavancin is effective against these pathogens and … Suite

Short or Long Durations of Therapy for Common Inpatient Infections Associated with Bacteremia? ( Hojat LS. et al. )

Effectiveness of Shorter Versus Longer Durations of Therapy for Common Inpatient Infections Associated with Bacteremia: A Multicenter, Propensity-Weighted Cohort Study.

09 jan | Dr Jean-Pierre Bru

No or few national guidelines for pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin and skin structure infection … Suite

Lefamulin versus moxifloxacin for the treatment of community-acquired bacterial pneumonia. Results of a phase III trial. ( File TM. et al. )

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

19 déc | Dr Jean-Pierre Bru

Lefamulin is a pleuromutilin antibiotic. Its name comes from the pleuromutilin-producing fungus Pleurotus mutilus. Previous pleuromutilin are already used : … Suite

Effective combination therapy does not seem to provide any benefit for the treatment of Stenotrophomonas maltophilia pneumonia. ( Shah MD. et al. )

Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia.

21 nov | Dr Olivier Leroy

Stenotrophomonas maltophilia is an emerging nosocomial pathogen more and more often responsible for respiratory tract infections. It is intrinsically resistant … Suite